Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829311 | 0.84 | RAB9A (0.43) | LMNAALDH1A1HIF1ASMN1; SMN2KDM4E | |
| SCHEMBL4833921 | 0.83 | ERN1 (0.47) | ALDH1A1HIF1ASMN1; SMN2 | |
| SCHEMBL4836369 | 0.83 | PTGS2 (0.42) | LMNAALDH1A1HIF1APTGS1SMN1; SMN2 | |
| SCHEMBL4829107 | 0.83 | PRMT5 (0.40) | LMNAALDH1A1HIF1APTGS1SMN1; SMN2 | |
| SCHEMBL3630473 | 0.83 | NR3C2 (0.41) | LMNAALDH1A1HIF1AKDM4EPTGS2 | |
| SCHEMBL4833849 | 0.81 | PRMT5 (0.44) | ALDH1A1HIF1APTGS1KDM4EPTGS2 | |
| SCHEMBL4829235 | 0.81 | PRMT5 (0.44) | LMNAALDH1A1HIF1ASMN1; SMN2NPC1 | |
| SCHEMBL4831072 | 0.80 | MEN1 (0.44) | LMNAALDH1A1KDM4EMAPTPRMT5 | |
| SCHEMBL4829106 | 0.80 | PTGS1 (0.54) | LMNAALDH1A1PTGS1SMN1; SMN2KDM4E | |
| SCHEMBL4829098 | 0.80 | PTGS1 (0.54) | LMNAALDH1A1PTGS1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| CN-101687790-B | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) | ABBVIE INC | 2015-02-11 | — | — | CN | disclosed |
| CN-101687790-A | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) | ABBOTT GMBH & CO KG | 2010-03-31 | — | — | CN | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | LMNA 2405/4885ALDH1A1 2652/4885HIF1A 1521/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | LMNA 2405/4885ALDH1A1 2652/4885HIF1A 1521/4885 |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | LMNA 4827/4885ALDH1A1 3335/4885HIF1A 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.